BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 22895534)

  • 1. Adenoviral neutral endopeptidase gene delivery in combination with paclitaxel for the treatment of prostate cancer.
    Iida K; Zheng R; Shen R; Nanus DM
    Int J Oncol; 2012 Oct; 41(4):1192-8. PubMed ID: 22895534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lentiviral vector neutral endopeptidase gene transfer suppresses prostate cancer tumor growth.
    Horiguchi A; Zheng R; Goodman OB; Shen R; Guan H; Hersh LB; Nanus DM
    Cancer Gene Ther; 2007 Jun; 14(6):583-9. PubMed ID: 17415380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutral endopeptidase inhibits prostate cancer tumorigenesis by reducing FGF-2-mediated angiogenesis.
    Horiguchi A; Chen DY; Goodman OB; Zheng R; Shen R; Guan H; Hersh LB; Nanus DM
    Prostate Cancer Prostatic Dis; 2008; 11(1):79-87. PubMed ID: 17563767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of neutral endopeptidase and activation of protein kinase B (Akt) is associated with prostate cancer progression.
    Osman I; Dai J; Mikhail M; Navarro D; Taneja SS; Lee P; Christos P; Shen R; Nanus DM
    Cancer; 2006 Dec; 107(11):2628-36. PubMed ID: 17083125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-suppressive effects of neutral endopeptidase in androgen-independent prostate cancer cells.
    Dai J; Shen R; Sumitomo M; Goldberg JS; Geng Y; Navarro D; Xu S; Koutcher JA; Garzotto M; Powell CT; Nanus DM
    Clin Cancer Res; 2001 May; 7(5):1370-7. PubMed ID: 11350908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of PTEN gene therapy and radiation inhibits the growth of human prostate cancer xenografts.
    Anai S; Goodison S; Shiverick K; Iczkowski K; Tanaka M; Rosser CJ
    Hum Gene Ther; 2006 Oct; 17(10):975-84. PubMed ID: 16984224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylseleninic acid enhances taxane drug efficacy against human prostate cancer and down-regulates antiapoptotic proteins Bcl-XL and survivin.
    Hu H; Li GX; Wang L; Watts J; Combs GF; Lü J
    Clin Cancer Res; 2008 Feb; 14(4):1150-8. PubMed ID: 18281549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel selenonucleoside suppresses tumor growth by targeting Skp2 degradation in paclitaxel-resistant prostate cancer.
    Byun WS; Jin M; Yu J; Kim WK; Song J; Chung HJ; Jeong LS; Lee SK
    Biochem Pharmacol; 2018 Dec; 158():84-94. PubMed ID: 30292755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel.
    Yu DC; Chen Y; Dilley J; Li Y; Embry M; Zhang H; Nguyen N; Amin P; Oh J; Henderson DR
    Cancer Res; 2001 Jan; 61(2):517-25. PubMed ID: 11212244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutral endopeptidase inhibits neuropeptide-mediated transactivation of the insulin-like growth factor receptor-Akt cell survival pathway.
    Sumitomo M; Milowsky MI; Shen R; Navarro D; Dai J; Asano T; Hayakawa M; Nanus DM
    Cancer Res; 2001 Apr; 61(8):3294-8. PubMed ID: 11309283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases.
    Uehara H; Kim SJ; Karashima T; Shepherd DL; Fan D; Tsan R; Killion JJ; Logothetis C; Mathew P; Fidler IJ
    J Natl Cancer Inst; 2003 Mar; 95(6):458-70. PubMed ID: 12644539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tunicamycin potentiates paclitaxel-induced apoptosis through inhibition of PI3K/AKT and MAPK pathways in breast cancer.
    Huang S; Wang D; Zhang S; Huang X; Wang D; Ijaz M; Shi Y
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):685-696. PubMed ID: 28779263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells.
    Natsagdorj A; Izumi K; Hiratsuka K; Machioka K; Iwamoto H; Naito R; Makino T; Kadomoto S; Shigehara K; Kadono Y; Lin WJ; Maolake A; Mizokami A
    Cancer Sci; 2019 Jan; 110(1):279-288. PubMed ID: 30426599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell specific expression of CD10/neutral endopeptidase 24.11 gene in human prostatic tissue and cells.
    Song J; Aumüller G; Xiao F; Wilhelm B; Albrecht M
    Prostate; 2004 Mar; 58(4):394-405. PubMed ID: 14968440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FAM46C inhibits cell proliferation and cell cycle progression and promotes apoptosis through PTEN/AKT signaling pathway and is associated with chemosensitivity in prostate cancer.
    Ma L; He H; Jiang K; Jiang P; He H; Feng S; Chen K; Shao J; Deng G
    Aging (Albany NY); 2020 Apr; 12(7):6352-6369. PubMed ID: 32283544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of human colon tumor growth by adenoviral vector-mediated NK4 expression in an athymic mouse model.
    Jie JZ; Wang JW; Qu JG; Hung T
    World J Gastroenterol; 2007 Apr; 13(13):1938-46. PubMed ID: 17461494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.
    Caraglia M; Marra M; Leonetti C; Meo G; D'Alessandro AM; Baldi A; Santini D; Tonini G; Bertieri R; Zupi G; Budillon A; Abbruzzese A
    J Cell Physiol; 2007 May; 211(2):533-43. PubMed ID: 17192846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microbubble-assisted p53, RB, and p130 gene transfer in combination with radiation therapy in prostate cancer.
    Nande R; Greco A; Gossman MS; Lopez JP; Claudio L; Salvatore M; Brunetti A; Denvir J; Howard CM; Claudio PP
    Curr Gene Ther; 2013 Jun; 13(3):163-74. PubMed ID: 23531191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) in combination with paclitaxel (Taxol) on prostate Cancer LNCaP cells cultured in vitro or grown as xenograft tumors in immunodeficient mice.
    Zheng X; Chang RL; Cui XX; Avila GE; Hebbar V; Garzotto M; Shih WJ; Lin Y; Lu SE; Rabson AB; Kong AN; Conney AH
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3444-51. PubMed ID: 16740769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel PI3K inhibitor displays potent preclinical activity against an androgen-independent and PTEN-deficient prostate cancer model established from the cell line PC3.
    Shi M; Zhou X; Zhang Z; Wang M; Chen G; Han K; Cao B; Liu Z; Mao X
    Toxicol Lett; 2014 Aug; 228(3):133-9. PubMed ID: 24831963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.